The estimated Net Worth of William W. Ericson is at least $4.72 Million dollars as of 15 March 2023. Mr. Ericson owns over 25,000 units of Pacific Biosciences of California Inc stock worth over $44,244 and over the last 14 years he sold PACB stock worth over $4,552,530. In addition, he makes $127,333 as Independent Director at Pacific Biosciences of California Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Ericson PACB stock SEC Form 4 insiders trading
William has made over 19 trades of the Pacific Biosciences of California Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 25,000 units of PACB stock worth $63,500 on 15 March 2023.
The largest trade he's ever made was buying 300,000 units of Pacific Biosciences of California Inc stock on 15 April 2014 worth over $4,800,000. On average, William trades about 23,150 units every 60 days since 2010. As of 15 March 2023 he still owns at least 26,336 units of Pacific Biosciences of California Inc stock.
You can see the complete history of Mr. Ericson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
William Ericson biography
William W. Ericson J.D. serves as Independent Director of the Company. Mr. Ericson has been the Founding Partner at Wildcat Venture Partners since 2016 where he focuses on investments in Digital Health. He is also a Managing Partner at Mohr Davidow Ventures (MDV) where he has led the firm’s focus on personalized medicine investing since 2003. Mr. Ericson has also served as a director of Adamas Pharmaceuticals, Inc. since 2005. Mr. Ericson holds a B.S.F.S. from Georgetown University School of Foreign Service and a J.D. from Northwestern University School of Law.
What is the salary of William Ericson?
As the Independent Director of Pacific Biosciences of California Inc, the total compensation of William Ericson at Pacific Biosciences of California Inc is $127,333. There are 4 executives at Pacific Biosciences of California Inc getting paid more, with Michael Hunkapiller having the highest compensation of $859,188.
How old is William Ericson?
William Ericson is 61, he's been the Independent Director of Pacific Biosciences of California Inc since 2020. There are 6 older and 12 younger executives at Pacific Biosciences of California Inc. The oldest executive at Pacific Biosciences of California Inc is Lucy Shapiro, 79, who is the Independent Director.
What's William Ericson's mailing address?
William's mailing address filed with the SEC is PACIFIC BIOSCIENCES OF CALIFORNIA, INC., 1305 O'BRIEN DRIVE, MENLO PARK, CA, 94025.
Insiders trading at Pacific Biosciences of California Inc
Over the last 14 years, insiders at Pacific Biosciences of California Inc have traded over $95,441,111 worth of Pacific Biosciences of California Inc stock and bought 2,252,330 units worth $6,097,136 . The most active insiders traders include Michael Hunkapiller, John F Milligan, and Christian O Henry. On average, Pacific Biosciences of California Inc executives and independent directors trade stock every 44 days with the average trade being worth of $202,112. The most recent stock trade was executed by Jeff Eidel on 19 August 2024, trading 26,760 units of PACB stock currently worth $42,548.
What does Pacific Biosciences of California Inc do?
pacbio develops comprehensive solutions for scientists that propel the field of genomics, improve science and research, and create positive impact globally. we provide sophisticated genomic analysis systems that deliver invaluable insights for scientists who strive to resolve complex genetic challenges. our strength comes from the dedication of our people, who are fueled by a desire to effect real, positive change. with a focus on the future and an experienced, passionate team, we are motivated to continue to redefine what is possible in genomics.
What does Pacific Biosciences of California Inc's logo look like?
Complete history of Mr. Ericson stock trades at Adamas Pharmaceuticals Inc and Pacific Biosciences of California Inc
Pacific Biosciences of California Inc executives and stock owners
Pacific Biosciences of California Inc executives and other stock owners filed with the SEC include:
-
Michael Hunkapiller,
Director -
Christian O. Henry M.B.A.,
Pres, CEO & Director -
Susan G. Kim,
Chief Financial Officer -
Dr. Denis Zaccarin Ph.D.,
Sr. VP of R&D -
William Ericson,
Independent Director -
Randall Livingston,
Independent Director -
Marshall Mohr,
Independent Director -
John Milligan,
Independent Chairman of the Board -
Lucy Shapiro,
Independent Director -
Kathy Ordonez,
Director -
Christian Henry,
President, Chief Executive Officer, Director -
David Botstein,
Independent Director -
Susan Kim,
Chief Principal Officer, Chief Accounting Officer -
Eric Schaefer,
Chief Accounting Officer, Vice President -
Denis Zaccarin,
Vice President - Semiconductor Integration Devices -
Chris Seipert,
Vice President, Sales, Service & Support, EMEA and America -
Kathleen Lynch J.D.,
Head of Global Gov. Affairs & Corp. Communications -
Michele Farmer CPA,
VP & Chief Accounting Officer -
Kathleen Lynch,
Head of Global Gov. Affairs & Corp. Communications -
Brett Atkins J.D., Ph.D.,
Gen. Counsel & Corp. Sec. -
Trevin Rard,
Head of Investor Relations -
Dr. Jonas Korlach Ph.D.,
Chief Scientific Officer -
Michele Farmer,
VP & Chief Accounting Officer -
Mark Van Oene,
Chief Operating Officer -
Dr. Stephen Turner,
Co-Founder & CTO -
James Michael Phillips,
SVP, Research & Development -
Susan K Barnes,
EVP, CFO and PAO -
Kevin P Corcoran,
SVP, Market Development -
Brook H Byers,
Director -
Jeff Eidel,
See Remarks -
Brian B Dow,
VP and PAO -
Michael Glynn,
Chief Commercial Officer -
David B Singer,
Director -
Susan E Siegel,
Director -
Hugh C Martin,
Chairman, CEO & President -
Stephen W Turner,
VP & Chief Technology Officer -
Hannah Valantine,
Director -
Oene Mark Van,
See Remarks -
Peter Fromen,
See Remarks -
Michele Farmer,
See Remarks -
David W Meline,
Director